Background: Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disease characterized by synovial inflammation, immune-mediated joint destruction, and systemic manifestations. While current disease-modifying antirheumatic drugs (DMARDs) and biologics—have advanced disease control, long-term use is limited by toxicity and immunosuppression. These limitations underscore a growing need for integrative strategies that combine conventional immunomodulators with targeted phytotherapy and modern drug delivery technologies. Objectives: This review explores mechanistically driven, combinatorial therapeutic approaches in RA that integrate Phytoconstituents, essential mineral cofactors, conventional DMARDs, and classical Ayurvedic formulations. Emphasis is placed on the application of nanobiotechnological platforms like solid lipid nanoparticles (SLNs), nanoemulgels and SMEDDSto enhance joint-targeted delivery, bioavailability, and immunological precision. Methods: A structured review of preclinical, pharmacokinetic, clinical, and regulatory literature was conducted using databases such as PubMed, Scopus, and Web of Science. Articles were critically evaluated for their insights into inflammatory signaling modulation (e.g., NF-κB, JAK/STAT, MAPK), pharmacological synergy, redox regulation, and nanocarrier-mediated macrophage targeting in RA. Policy frameworks from CDSCO, FDA, EMA, and AYUSH were also reviewed to contextualize translational feasibility. Results: Several phytochemical-based combinations—such as curcumin with boswellic acids, and guggulsterone with methotrexate—exhibit additive or synergistic modulation of cytokine cascades, redox balance, and osteoclastogenesis. Nanocolloidal systems significantly enhance the pharmacokinetics and synovial targeting of lipophilic actives via passive (EPR effect) and active (e.g., folate receptor-mediated) uptake. These bioengineered platforms have demonstrated improved therapeutic outcomes minimized systemic toxicity. However, challenges persist in standardization of Phytoconstituents and clinical trial validation. Conclusion: Integrative nanobiotechnology—bridging traditional phytotherapy with modern delivery science—represents a transformative paradigm for personalized and precision-based RA management. Guggul-based nanophytomedicine offers a compelling alternative or adjunct to conventional DMARDs by targeting inflammatory and oxidative networks with enhanced specificity. To fully harness these advances, future efforts must focus on harmonized regulatory models, robust clinical evaluation, and scalable manufacturing infrastructure.
Ravouru et al. (Mon,) studied this question.